Novo Nordisk's work goes beyond diabetes and obesity, which are currently its core areas. The drugmaker has been looking to diversify its lineup for years. For one, semaglutide, the active ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk ... and 2.4 mg semaglutide once-weekly," the ...

semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweigh Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk ...

The results are a boost to Novo Nordisk after another weight-loss therapy, CagriSema (cagrilintide and semaglutide), delivered lower-than-hoped-for weight loss of 20.4% at 68 weeks in a phase 3 ...

Novo Nordisk’s semaglutide reduced major cardiovascular events by 26% in high-risk adults with type 2 diabetes, according to new data. Diabetes patients are particularly at risk of major ...

Novo Nordisk is an innovative company targeting ... more that could earn approval within the next few years. Further, semaglutide, the active ingredient in Wegovy and Ozempic (a diabetes medicine ...